SCHEMBL18220195

SCHEMBL18220195

COCCNS(=O)(=O)/C(C#N)=C(\C)c1ccc(-c2ccc3cc(N4CCN(C)CC4)ccc3c2)n1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.43
PRKD1 Q15139 1/20 0.34
KCNH2 Q12809 2/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
RXFP1 Q9HBX9 2/20 0.34
HTR3A P46098 1/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
PIM1 P11309 1/20 0.32
PIM3 Q86V86 1/20 0.32
POLB P06746 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
ATM Q13315 1/20 0.32
GUSB P08236 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
ABL1 P00519 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220201 0.94 APP (0.42) APPKCNH2DRD2DRD3RXFP1
SCHEMBL18220198 0.92 APP (0.43) APPKCNH2DRD2DRD3CA1
SCHEMBL18221528 0.85 CDK4 (0.33) APPPRKD1KCNH2DRD2DRD3
SCHEMBL18220236 0.85 CTSK (0.34) APPPRKD1KCNH2DRD2DRD3
SCHEMBL18220008 0.85 APP (0.48) APPPRKD1RXFP1HTR3APOLB
SCHEMBL18220148 0.84 APP (0.43) APPPRKD1KCNH2POLBALDH1A1
SCHEMBL18220214 0.83 KDM4E (0.31) ALDH1A1MAPT
SCHEMBL18220176 0.83 APP (0.43) APPPRKD1RXFP1HTR3APOLB
SCHEMBL18220206 0.83 APP (0.44) APPPRKD1KCNH2DRD2DRD3
SCHEMBL18220187 0.83 APP (0.47) APPPRKD1RXFP1HTR3ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885PRKD1 3969/4885KCNH2 4470/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885PRKD1 3969/4885KCNH2 4470/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885PRKD1 4009/4885KCNH2 4460/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885PRKD1 4009/4885KCNH2 4460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.